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Objectives. This study sought to determine, in vivo, whether
electromagnetic interference (EMI), generated by North Amer-
ican Digital Communications (NADC)/Time Division Multiple
Access–50-Hz (TDMA-50) mobile cellular digital telephone
model AT&T 6650, disturbs normal implantable cardioverter-
defibrillator (ICD) operation and to verify these observations
in vitro by testing a selection of telephones representing
worldwide systems.
Methods. The effects of cellular phone interference on the
operation of various models of market-released ICDs from a
single manufacturer, Medtronic, Inc., were tested. The in vivo
clinical test was undertaken in 41 patients using the AT&T 6650
digital telephone with the NADC/TDMA-50 technology. The in
vitro component of the study was examined twofold: 1) antenna
generated far field; and 2) analog/digital cellular telephone near
field.
Results. None of the ICDs tested in 41 patients were affected by
oversensing of the EMI field of the cellular telephones during the
in vivo study. Therefore, the binomial upper 95% confidence limit
for the failure rate of 0% is 7%. The in vitro antenna-generated
field testing showed that telephone modulation frequencies used
in the international Global System Mobile and TDMA-50 cellular
telephone technologies did not result in ICD sensing interference
at the predicted electric field intensity. The in vitro near field tests
were performed using both analog and digital cellular telephones
in service, or in the test mode, and indicated no interaction with
normal operation. However, the static magnetic field generated
by the cellular telephone placed over the ICD at a distance
<20.5 cm will activate the internal reed switch, resulting in
temporary suspension of ventricular tachycardia and fibrilla-
tion detection.
Conclusions. We conclude that TDMA-50 cellular telephones
did not interfere with these types of ICDs. However, we recom-
mend that the patient not carry or place the digital cellular
telephone within 15 cm (6 in.) of the ICD.
(J Am Coll Cardiol 1998;31:623–8)
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The interaction of analog and digital mobile cellular tele-
phones with pacemakers and defibrillators has been the subject
of considerable recent interest (1). However, most existing
studies have focused primarily on mobile cellular telephone
interaction with pacemakers. For example, Hayes et al. (2)
tested 980 patients with cardiac pacemakers with analog and
digital cellular telephones and found a 20% incidence of
interference. Similarly, Carrillo et al. (3) reported findings in
59 patients who did not depend on a pacemaker and who had
digital telephones. Interference was seen in 21 patients
(36.2%) and 19 pacemaker models (54%) when the telephone
was held over the pacemaker. Subsequently, a pilot study of 30
patients who did not depend on a pacemaker and who had
digital telephones showed tracking interference on the atrial
lead, oversensing and undersensing in 16 patients (53%) (4). In
contrast, another study examining the effects of interference
from analog cellular telephones found no evidence of electro-
cardiographic (ECG) abnormalities with 24 implanted pace-
makers (5). To date, there has not been any reported perma-
nent damage, pacemaker dysfunction or changes in the
program variables observed during these studies.
The risk to the patient caused by cellular telephone inter-
ference with an implantable cardioverter-defibrillator (ICD)
could potentially be greater than that with a pacemaker. Any
electromagnetic interference (EMI) with an ICD—that is,
interference with its normal operation, thereby causing other
inappropriate sensing and uncalled for shocks, or alternatively
temporary suspension of arrhythmia detection—could be un-
pleasant or even life-threatening.
The objectives of this study were first to evaluate the
susceptibility of tiered, single-chamber ICDs to EMI caused by
commercially available digital mobile telephones during in vivo
clinical testing, and second to confirm in vivo observations by
in vitro tests using analog and digital cellular phones and
antenna-generated fields. The ultimate goal was to provide
guidelines regarding the safe use of mobile cellular telephones
by patients with an ICD.
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Methods
In vivo testing. Patients and device configuration. The study
group consisted of 41 patients (7 women and 34 men).
Twenty-one patients had a model 7217 PCD cardioverter-
defibrillator (Medtronic, Inc.) implanted in an abdominal
location, and 20 had a model 7219 Jewel ICD—18 in the
pectoral region (6 subcutaneous and 12 deep to the pectoralis
major muscle) and 2 in the abdominal region. Forty of the
ICDs were connected to bipolar lead systems. One lead system
consisted of an integrated bipolar design. Thirty-five of the
patients had an implanted transvenous ventricular lead with 34
leads (Medtronic model 6936) consisting of polyurethane
insulation and coaxial wound conductors, a high voltage coil, a
ring and active fixation helix at 12-mm spacing for bipolar
sensing and one lead (Cardiac Pacemaker, Inc., model 0115)
consisting of silicone insulation with multilumen conductors, a
high voltage coil and a passive fixation electrode with 12-mm
spacing for integrated sensing implanted in the right ventricu-
lar apex. Six of the patients had an epicardial lead system
consisting of two unipolar active fixation leads (Medtronic
model 6917) with a nominal separation of 2 cm between
electrodes, connected in a bipolar configuration. The separa-
tion between the lead conductors varied during the length of
the lead, and any excess length was coiled at the implantation
site, which would have very little effect on the antenna
properties of the lead.
Digital phones. The hand-held mobile telephone used for
all tests was an AT&T model 6650 capable of analog and
digital operation with 0.6 W peak power. The digital transmis-
sion mode in this North American Digital Communications/
Time Division Multiple Access–50-Hz (NADC/TDMA-50)
technology consists of an 828-MHz carrier signal modulated at
a 20-ms pulse period (50 Hz pulse rate). This telephone had
the advantage of displaying the actual power that was used
during a call.
Study protocol. All tests were thoroughly explained to each
patient, and consent was obtained and coordinated with the
primary care physician before commencing the test. All pa-
tients tested used the same mobile telephone at the same
location in the clinic. The transmitting power of the mobile
telephone was recorded for each patient test. All patients were
connected to an ECG monitor and continuously observed
during the tests. The tests were conducted with the telephone
ringing (receiving) and transmitting (calling) 1) at both the
right and left ears, simulating regular use; 2) moving over the
entire route of the lead from electrode in the heart to its
connector end; and 3) on top of the implantation site to
simulate carrying the telephone in the upper shirt pocket or at
the belt. All tests were with telephone configurations consisting
of the antenna withdrawn (in) into the base (strongest mag-
netic field) and the antenna fully extended (out) using the tip
(strongest electrical field). The ICDs tested in this study were
able to provide noninvasive, telemetered, internal event
counter information on detected episodes of ventricular tachy-
cardia or ventricular fibrillation. Specific variables were repro-
grammed to “worst case” values for this test (Table 1) to
enhance the probability that detection of EMI from the
cellular telephone would produce inappropriate device opera-
tion. The sensitivity was reprogrammed to the most sensitive
value, and the number of intervals to detect tachycardia or
fibrillation was set to the minimal value to satisfy the detection
algorithm. All tachycardia pacing and shock therapies were
temporarily disabled as a precaution in the event that the EMI
was sensed, thereby initiating therapy. The pacing rate was
increased ;10 ppm above the patient’s intrinsic rate to pro-
duce continuous overdrive pacing. The programmer head was
not left in place over the ICD during testing.
The defibrillator was interrogated after the patient com-
pleted each specific telephone test to determine whether the
ventricular tachycardia or fibrillation detection algorithms
were satisfied by detection of EMI. The telemetered data
would identify any detected episode of ventricular tachycardia
or fibrillation by indicating an increment in the internal
counter used to monitor for arrhythmia detection in the
Tachycardia Counter Data Report. All variables were repro-
grammed to original values after completion of the test.
The cellular telephone has a built-in speaker with a small,
permanent magnet in the earpiece that generates a static
magnetic field. A magnetic field could activate a reed switch in
the cardioverter-defibrillator and temporarily inhibit detection
of ventricular tachycardia or fibrillation. However, this mag-
netic field interference would not be detected in this in vivo
study, because, unlike standard pacemakers, the pacing circuit
of the ICDs being tested will not revert to an asynchronous
Abbreviations and Acronyms
ECG 5 electrocardiogram, electrocardiographic
EMI 5 electromagnetic interference
ICD 5 implantable cardioverter-defibrillator
GSM 5 Global System Mobile
NADC 5 North American Digital Communications
RMS 5 root-mean-square
TDMA-50 5 Time Division Multiple Access–50 Hz
Table 1. Implantable-Cardioverter Defibrillator Variables
Temporarily Reprogrammed During Clinical Testing
Variable Nominal Test
Sensitivity 0.3 mV 0.15 mV (model 7219)
0.3 mV 0.3 mV (model 7217)
No. of intervals to detect VT 16 4
No. of intervals to detect VF 18 of 24 12 of 16
VF detection On/320 ms On/400 ms
VT detection On/400 ms On/600 ms
VT/VF therapies On Off
Stability On or off Off
Onset On or off Off
Pacing rate — 10 ppm above intrinsic
ppm 5 pulses per minute; VF 5 ventricular fibrillation; VT 5 ventricular
tachycardia.
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pacing mode. Therefore, this test could not be done in vivo, but
was accomplished with a custom device during in vitro testing
(see In Vitro Testing, Magnet test).
Statistical analysis. An exact binomial upper 95% confi-
dence limit was used on the failure rate.
In vitro testing. Antenna-generated field. The ICD was
connected to either a transvenous or epicardial lead system.
The complete system was then immersed in a 375 6 15 ohm cm
saline solution bath and placed within 1 cm (typical implant
depth) of the liquid surface in a frontal orientation, as shown
in Figure 1. A transmitting antenna was connected to a
frequency pulse generator to simulate cellular telephone mod-
ulation. The testing was structured to assess susceptibility of
the ICD’s normal operation to modulations that are known to
be used in two digital cellular telephone systems: NADC/
TDMA-50 and international Global System Mobile (GSM).
Four models of ICDs—PCD 7217, Jewel 7219, Jewel Plus 7220
and Micro Jewel 7221—were subjected to radiated continuous
carrier wave and modulated interference fields at two
frequencies—836 MHz and 900 MHz. Modulations that sim-
ulate the digital systems patterns as shown in Table 2. The field
intensity was increased until the ICD began to sense the
interference, and the level at that point was recorded.
Analog/digital cellular phones. The ICDs listed in Table 3,
immersed in saline, were subjected to the near fields radiated
from the antennas of the cellular telephone models used in
North America and worldwide, as shown in Table 4. The
telephones were tested in both analog and digital modes,
where applicable. Some telephones, designated as group 1 in
Table 4, could be fully operated, and the susceptibility was
evaluated while the telephone was transmitting and receiving
calls with the antenna withdrawn (in) and extended (out).
Other technologies, designated as group 2 in Table 4, were
used in an open-loop transmit mode (i.e., producing the typical
pulsing format of that technology without being in communi-
cation with an active cell site or base station simulator).
Keypad programming was used to configure the telephone in
the full power transmit mode. The distance from the telephone
antenna to the ICD was kept within 1 cm.
Magnet test. A custom ICD was modified with special
software so that when the reed switch was activated with a
magnet, the pacing rate would change to a train of 7 pulses of
low amplitude and a fast rate (100 ppm), and then return to
normal pacing. The cellular telephone, with its magnet in the
earpiece, was brought into direct contact with the ICD in free
air and then moved around on and at incremental distances
from the surface while the pacing output was monitored.
Figure 1. Top view of tank simulation
model used for the antenna-generated
field in vitro test of the ICDs. Amp 5
amplifier; Atten 5 attenuator; EFG-2 5
electric field generator-2; Gen. 5 gener-
ator; RF VM 5 radiofrequency volt
meter.
Table 2. Antenna-Generated Fields Used to Simulate Digital
Cellular Telephone Technology Modulation During In Vitro Testing
of Implantable Cardioverter-Defibrillators*
Carrier
Frequency Modulation
Cellular Telephone
Technology
900 MHz 0.6 ms PW/480 ms PP (125 Hz) Global System Mobile
900 MHz 0.6 ms PW/120 ms PP (500 Hz) Global System Mobile
900 MHz 0.6 ms PW/4.61 ms PP (13 kHz) Global System Mobile
836 MHz 6.7 ms PW/20 ms PP (3 kHz) Time Division Multiple
Access–50 Hz
*See Table 3 for a list of the implantable cardioverter-defibrillators. PP 5
pulse period; PW 5 pulse width.
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Results
In vivo testing. Digital cellular phone. The ICD was inter-
rogated after each phase of telephone status and location
testing. At no time was any ventricular tachycardia or fibrilla-
tion counter activated by the EMI from the antenna of the
cellular telephone for any test conducted on any patient. There
was no damage or reprogramming of any ICD during the tests.
The ECG that was recorded continuously during the patient
test to monitor the ventricular demand overdrive pacing mode
(VVI) was thoroughly reviewed for abnormalities. At no time
were there any indications of pacing inhibition or changes to
the programmed pacing intervals during any test on any
patient. Therefore, the binomial upper 95% confidence limit
for the failure rate of 0% is 7%.
In vitro testing. Antenna-generated field testing. Field
strength levels at which the ICDs began to sense the interfer-
ence started at 230 V/m root-mean-square (RMS). Interfer-
ence oversensing resulted in partial inhibition (changed pacing
rates); satisfied the ventricular tachycardia or ventricular fibril-
lation detection algorithm and could have caused either ther-
apy to be delivered; or caused the device to go power-on-reset.
The most susceptible ICD to EMI was the early generation
model 7217 connected to a bipolar epicardial lead system that
occurred at field intensities of 230 V/m RMS. A bipolar,
coaxial, polyurethane, insulated, endocardial lead connected to
the model 7217 ICD increased the susceptibility interference
level to 300 V/m RMS.
Predicted field intensity. To estimate the field values in the
vicinity of the ICD, the predicted electric field intensity for a
0.6-W isotropic antenna point source, as recorded at measured
distances in free space from the antenna, is plotted in Figure 2.
The predicted electric field intensity (E) for a 0.6-W isotropic
antenna point source, as measured along axes in all directions
for free space conditions (air at 377 V), was calculated at
incremental distances from the transmitting antenna using the
following equation (6):
E 5
~30 P!1/2
R
~volts/meter!,
where P 5 transmitted power in watts (0.6 W), and R 5
distance in meters.
The field intensity decreases exponentially and rapidly
drops ,50 V/m RMS at 10 cm from the antenna. At 15 cm (6
in.), the distance recommended for cellular telephone use for
patients with ICDs, the field intensity would be 20 V/m RMS,
which is well below the susceptibility level measured during the
in vitro antenna-generated field testing. Field intensity predic-
tions at distances ,2 cm from the point source were not
attempted, as this near field also contains magnetic fields that
Table 3. In Vitro Test Results of Implantable Cardioverter-
Defibrillators Subjected to Near Field Effects of Analog and Digital
Telephone Technologies
ICD Model/Lead
System
Cellular Telephone Technology
AMPS GSM TDMA-50 TDMA-11 PCS
7217B/epicardial NE NE NE NE NE
7217B/endocardial NE NE NE NE NE
7219D/epicardial NE NE NE NE NE
7219D/endocardial NE NE NE NE NE
7219C/endocardial NE NE NE NE NE
7220D/epicardial NE NE NE NE NE
7220D/endocardial NE NE NE NE NE
7220C/endocardial NE NE NE NE NE
7221D/epicardial NE NE NE NE NE
7221C/endocardial NE NE NE NE NE
AMPS 5 Advanced Mobile Phone System; GSM 5 Global System Mobile;
NE 5 no effect; PCS 5 Personal Communications System; TDMA-11 5 Time
Division Multiple Access–11 Hz; TDMA-50 5 Time Division Multiple
Access–50 Hz.
Table 4. Analog and Digital Cellular Telephone Models Used
During In Vitro Testing for Near Field Effects on Implantable
Cardioverter-Defibrillators*
Cellular Telephone
Technology Cellular Telephone Model
Maximal Power
of Pulse (W)
Group 1
AMPS Motorola, model FOSHLD84168G NA
AMPS/TDMA-50 Motorola LE Bag Phone, model
19902XTLSA
5.0 (TDMA)
AMPS/TDMA-50 AT&T, model 6650 0.6†
Group 2
TDMA-11 (MIRS) Test transmitter 3.7
GSM Test transmitter 1.7
PCS Test transmitter 0.5
AMPS/TDMA-50 Test transmitter 1.0 (TDMA)
*See Table 3 for a list of the implantable cardioverter-defibrillators. †Power
value provided in the manufacturer’s technical manual. Group 1 5 cellular
telephone in service. Group 2 5 transmitter operated in test mode. NA 5 not
applicable; MIRS 5 Motorola Integrated Radio Services; other abbreviations as
in Table 3.
Figure 2. Theoretically predicted electric field intensity for a 0.6-W
isotropic point source antenna, as measured in axis in all directions in
air at incremental distances from the antenna.
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affect the accuracy of the equation. The near field character-
istics for the cellular technologies were assessed by in vitro
testing with the analog and digital cellular telephones.
Analog/digital cellular telephones. Testing was completed
and the results summarized (Table 3) on models of market-
released ICDs, and testing was completed on various lead
systems, with the analog/digital cellular telephones in groups 1
and 2 listed in Table 4. No interference was noticed on any
ICD with any cellular telephone technology.
Magnet test. The static magnetic field generated by the
magnet of the speaker in the telephone was measured to be
288 gauss RMS at the telephone surface and decreases expo-
nentially to 19 gauss at 1 cm (0.4 in.) from the surface. The
cellular telephone placed over and moved around on the ICD
surface activated the reed switch when the telephone was on
the upper left corner of the engraved side, where the reed
switch is located. When the cellular telephone was placed at
0.5 cm (0.2 in.) or further from the ICD surface, reed switch
activation did not occur.
Discussion
The findings of this study indicate that EMI transmitted by
digital cellular technologies, commonly used in North Amer-
ica, did not interfere with in vivo normal functional operation
of the specific ICDs tested. Inappropriate sensing did not occur
and ventricular tachycardia or fibrillation detection plus pacing
function remained normal. The average overdriven VVI pac-
ing rate of 80 ppm (750 ms) resulted in a postpace blanking
period of 320 ms, leaving 430 ms available for sensing during
each paced interval. The nonpaced blanking period was
120 ms, increasing the sensing period to 630 ms. However, the
test was designed so that the EMI was present for many pacing
cycles, allowing more than adequate time to detect interfer-
ence during the pace intervals, and similar results would be
expected for nonpaced rhythms. These results were substanti-
ated by comprehensive test data from independent in vitro
studies using digital telephone technologies used worldwide: 1)
antenna-generated field testing to evaluate far field interfer-
ence; and 2) in vitro analog and digital cellular telephone
testing that evaluated near field effects. In these in vitro studies
it was observed that the magnetic field from the earpiece
speaker magnet in the cellular telephone can activate the reed
switch in the ICD at distances ,0.5 cm (0.2 in.) and tempo-
rarily suspend ventricular tachycardia or fibrillation detection.
At this time there are few published data pertaining to
cellular telephone interference with ICDs. In one preliminary
report of 25 patients with ICDs, Stanton et al. (7) found that
North American–type analog and digital cellular telephones
did not cause any interference oversensing, arrhythmia over-
detection or interference with sensing or pacing. Similarly,
Madrid et al. (8), who assessed 40 patients with an ICD using
international, high power (3-W) analog cellular telephones,
found EMI in only one patient. In contrast, an in vitro study by
Bassen et al. (9), who tested the interference effect of digital
cellular phone modulation schemes used in North America on
four ICDs, noted that discharges occurred when the bases of
the antennae of certain model telephones were placed within
;5 cm from the header of the defibrillator or at branches of
bifurcated leads. An explanation for the discrepancy between
the results reported by Bassen et al. and those of our in vitro
tests may be related to their use of early models of unidentified
ICDs.
Bipolar versus unipolar sensing. Forty of the 41 ICDs
tested in this report used bipolar sensing; 34 of the 35
transvenous lead systems used standard true bipolar sensing
and 1 used integrated bipolar sensing. The remaining six lead
systems consisted of two epicardial unipolar leads configured
into a bipolar pair. Neither bipolar nor paired unipolar lead
systems exhibited susceptibility to EMI. In contrast, Irnich et
al. (10) conducted in vitro testing of mobile telephone inter-
ference with 44 pacemakers from the same manufacturer and
found that 5 (18.5%) of 27 unipolar systems and 4 (23.5%) of
17 bipolar units were susceptible. However, other studies
comparing bipolar to unipolar pacemaker susceptibility to
mobile cellular telephone interference indicated the superior-
ity of bipolar lead systems in rejecting EMI (11–13). Naegeli et
al. (14) tested 39 patients with pacemakers using digital mobile
telephones and found that when the incidence of VVIR
pacemaker inhibition was compared in the bipolar and unipo-
lar modes in the same patients, ventricular inhibition occurred
in none of the 112 tests in the bipolar mode compared with 14
(12.5%) of the 112 tests in the unipolar mode.
Interference rejection mechanisms. The ICD and lead
system were scanned with the cellular telephone antenna
during telephone operation and in vitro near field testing. It
was observed that scanning over any portion of the lead
produced no interference effects to the ICD. Electromagnetic
interference on pacemakers was observed to be the greatest
when the antenna was extended and located over the header
assembly. The effect could not be duplicated during this study
in the ICDs. The susceptibility at the header and lack of
substantial lead contribution to EMI were substantiated during
in vitro studies with pacemakers by Carrillo et al. (15). Much of
the energy injected at the tip electrode and along the length of
the lead is attenuated to the surrounding medium (cardiac
tissue in vivo and saline in vitro) along the entire length of the
lead. Generally, on all manufacturers’ ICDs, the feedthroughs
and connecting wires to the sense amplifier on the hybrid
circuit, although short in length, act as an antenna to the high
frequency (short wavelength) interference signal. Protection to
the sense amplifier for the ICDs tested in this study was
accomplished with capacitors on the input to the sense ampli-
fier located on the hybrid circuit. The differential input con-
figuration and very high input impedance of the sense amplifier
will also contribute to cancellation of interference signals
appearing on each conductor of the bipolar lead.
It has been observed during patient testing that the implan-
tation techniques did not have any relation to interference
detection by the ICD. It has been implied in other published
reports that the thick layer of pectoralis muscle or abdominal
muscle would reduce interference penetration compared with
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a subcutaneous pocket where the device is closer to the surface
skin (16). However, the magnetic field of the radiated energy
penetrates through the skin and muscle, subjecting the im-
planted device to a significant amount of interference energy.
Six of the 41 patients tested had their cardioverter-defibrillator
implanted subcutaneously, but showed no difference in their
susceptibility to EMI. A subpectoral or abdominal implant
would increase the distance between the cellular telephone
and implantable device and reduce the potential for reed
switch activation by the speaker magnet.
Study limitations. The patients were tested with a single-
model cellular telephone capable of analog and digital opera-
tion (AT&T model 6650), using the NADC/TDMA-50 tech-
nology with 0.6 W peak power. The in vitro antenna-generated
test and the analog/digital cellular telephone test were com-
prehensive enough to include the main cellular telephone
technologies, with the exception of Code Division Multiplex
Access, as the equipment was not available at the time of this
study. All tests were conducted using one manufacturer’s
ICDs, because identical models of devices required for the in
vivo and analogous in vitro tests, including modified custom
devices, were unavailable from other manufacturers. The lead
system tested was primarily a bipolar configuration, because
the manufacturer of the ICDs tested did not produce any
integrated bipolar leads at that time. In vivo testing was not
performed during ventricular fibrillation, as the clinical proto-
col did not include this type of patient test. However, the tests
described herein, performed without ventricular fibrillation,
have shown that the ICDs were not susceptible to EMI, and
therefore would not hinder normal ventricular fibrillation
detection. Further studies are required with an expanded
representation of ICDs and leads and different new genera-
tions of cellular telephones to access any changes in the devices
that would affect interference potentials.
Clinical implications and conclusions. We conclude that
typical NADC/TDMA-50 cellular telephones with 0.6 W
power do not appear to interfere with the in vivo operation of
specific ICD systems. Damage or reprogramming to any of the
tested ICDs during use of the cellular telephone would seem to
be highly unlikely. Nevertheless, provision of a transvenous
bipolar lead system could provide an additional measure of
resistance to sensing interference energy fields.
In contrast, there is a potential for temporary suspension of
ventricular tachycardia and fibrillation detection from the
static magnetic field generated by the speaker in the cellular
telephone earpiece only if the telephone is placed directly on
top of and at a distance ,0.5 cm from the cardioverter-
defibrillator—primarily those implanted in a subcutaneous
pocket. It would be prudent to provide an extra margin of
safety when patients implanted with a cardioverter-
defibrillator use a cellular telephone by 1) maintaining a
minimal separation of 15 cm (6 in.) between a 0.6-W cellular
phone and antenna to the implanted device and 30 cm (12 in.)
for telephones with power .3 W; 2) holding the telephone to
the ear opposite the side of the implanted device; 3) not
holding the telephone near their chest while dialing or con-
versing, nor carrying the telephone in a breast pocket or on a
belt within 15 cm (6 in.) of the implanted device, regardless of
whether it is not in use; and 4) storing the telephone in a
location opposite the side of the implanted device.
References
1. Hayes DL, Carrillo RG, Findlay GK, et al. State of science: pacemaker and
defibrillator interference from wireless communication devices. PACE 1996;
19:1490–30.
2. Hayes DL, Wang PL, Reynolds DW, et al. Interference with cardiac
pacemakers by cellular telephones. N Engl J Med 1997;336:1473–9.
3. Carrillo R, Saunkeah B, Pickets M, et al. Preliminary observations on
cellular telephones and pacemakers [abstract]. PACE 1995;18:863.
4. Hayes DL, Von Feldt L, Neubauer S, et al. Effect of digital cellular phones
on permanent pacemakers [abstract]. PACE 1995;18:863.
5. Hayes DL, Von Feldt LK, Neubauer SA, et al. Does cellular phone
technology cause pacemaker or defibrillator interference? [abstract] PACE
1995;18:842.
6. Reference Data for Radio Engineers. 4th ed. New York: Stratford Press,
1960:674–6.
7. Stanton MS, Grice SE, Trusty J, et al. Safety of various cellular phone
technologies with implantable cardioverter defibrillators [abstract]. PACE
1996;19:583.
8. Madrid AH, Concepcion M, Chadi MD. Interference between automatic
defibrillators and mobile phones [abstract]. PACE 1996;19:676.
9. Bassen H, Moore HJ, Ruggers PS. Cellular phone interference testing of
implantable cardiac defibrillators, in vitro [abstract]. Circulation 1995;92
Suppl I:I-738.
10. Inrich W, Batz L, Muller R, et al. Electromagnetic interference on pace-
makers by mobile phones. PACE 1996;19:1431–46.
11. Andreas W, Grimm W, Funck R, et al. Influence of D-Net (European
GSM-Standard) cellular phones on pacemaker function in 50 patients with
permanent pacemakers. PACE 1996;19:1456–8.
12. Grimm W, Wilke A, Hoffmann J, et al. Interactions between handy phones
and pacemaker function in patients with permanent pacemakers [abstract].
J Am Coll Cardiol 1995;25:912–39.
13. Sparks PB, Mond HG, Joyner KH, et al. The safety of digital mobile cellular
telephones with minute ventilation rate adaptive pacemakers. PACE 1996;
19:1451–5.
14. Naegeli B, Osswald S, Deola M, et al. Intermittent pacemaker dysfunction
caused by digital mobile telephones. J Am Coll Cardiol 1996;27:1471–7.
15. Carrillo R, Garay O, Balzano Q, et al. Electromagnetic near field interfer-
ence with implantable medical devices. IEEE 1995 International Symposium
on Electromagnetic Compatibility. Piscataway (NJ): IEEE, 1995:1–3.
16. Inrich W. Mobile telephones and pacemakers. PACE 1996;19:1407–9.
628 FETTER ET AL. JACC Vol. 31, No. 3
CELLULAR TELEPHONE INTERACTION WITH DEFIBRILLATORS March 1, 1998:623–8
